Moderna R&D: Funding shifts impacting pipelines?

Just a thought I wanted to throw out there for discussion. Seeing some chatter online and hearing whispers internally about how changes in government funding and overall biotech investment climate might be affecting R&D priorities here at Moderna. It feels like there's a lot more scrutiny on early-stage projects, and some areas that were previously getting a lot of attention seem to have cooled off considerably. This isn't about specific layoffs (yet, thankfully), but more about the strategic direction and resource allocation. Are other R&D folks feeling this pressure? Is it leading to slower progress on certain fronts, or are we just re-aligning to focus on the most promising avenues? Curious to hear perspectives from scientists, researchers, and even project managers about how these external financial factors are translating into day-to-day work and long-term project viability. It's a tough market out there, and I wonder how it's shaping our internal roadmap.